FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280494789> ?p ?o ?g. }

• W4280494789 abstract "News & Views16 May 2022Open Access ASC nanobodies to counteract the consequences of inflammasome activation Sahil Adriouch Sahil Adriouch orcid.org/0000-0002-0265-7773 UNIROUEN, INSERM, U1234 (PANTHER), Normandie University, Rouen, France Search for more papers by this author Pablo Pelegrin Corresponding Author Pablo Pelegrin [email protected] orcid.org/0000-0002-9688-1804 Biomedical Research Institute of Murcia (IMIB), University of Murcia, Murcia, Spain Contribution: Writing - original draft, Writing - review & editing Search for more papers by this author Sahil Adriouch Sahil Adriouch orcid.org/0000-0002-0265-7773 UNIROUEN, INSERM, U1234 (PANTHER), Normandie University, Rouen, France Search for more papers by this author Pablo Pelegrin Corresponding Author Pablo Pelegrin [email protected] orcid.org/0000-0002-9688-1804 Biomedical Research Institute of Murcia (IMIB), University of Murcia, Murcia, Spain Contribution: Writing - original draft, Writing - review & editing Search for more papers by this author Author Information Sahil Adriouch1 and Pablo Pelegrin *,2 1UNIROUEN, INSERM, U1234 (PANTHER), Normandie University, Rouen, France 2Biomedical Research Institute of Murcia (IMIB), University of Murcia, Murcia, Spain *Corresponding author. E-mail: [email protected] EMBO Mol Med (2022)14:e16087https://doi.org/10.15252/emmm.202216087 See also: D Bertheloot et al (June 2022) PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Inflammasomes are multiprotein complexes that signal by oligomerizing the apoptosis speck-like protein with caspase recruitment and activator domain (ASC) and are involved in multiple inflammatory, metabolic and degenerative diseases. Pharmacological targeting of specific inflammasomes with small molecules is leading to the development of novel drugs for most common diseases. The targeting of ASC oligomers will result in a pan-inflammasome treatment. In their study, Bertheloot et al (2022) developed specific anti-ASC nanobodies and showed their efficacy to disaggregate already formed ASC oligomers and to treat inflammatory diseases in animal models. This approach represents a novel biologic-based treatment for inflammasomes-initiated inflammatory diseases. Inflammasomes are composed of a sensor protein that, upon activation, recruit ASC into large helicoidal filaments that activate caspase-1 by bringing pro-caspase-1 zymogens into close proximity. Caspase-1 is the effector enzyme of the inflammasome, and by cleaving the pore-forming protein gasdermin D (GSDMD), it mediates a specific type of necrotic-like cell death called pyroptosis. The resulting N-terminal fragment of GSDMD inserts into the plasma membrane and self-oligomerizes, leading to the formation of pores of around 10–15 nm in inner diameter that allows the release of pro-inflammatory cytokines and other intracellular content able to initiate and amplify the inflammatory response (Broz et al, 2020). GSDMD pore leads to consequent permeabilization of the plasma membrane and the release of large-cellular associated content, as ASC oligomers and other pro-inflammatory intracellular mediators that further propagate inflammasome signalling (Baroja-Mazo et al, 2014; Franklin et al, 2014). In fact, extracellular ASC oligomers have been implicated in the pathophysiology of multiple inflammatory-related diseases, such as chronic obstructive pulmonary disease, cryopyrin-associated periodic syndromes, sepsis, Alzheimer’s disease, non-alcoholic fatty liver disease and liver fibrosis (Baroja-Mazo et al, 2014; Franklin et al, 2014; Venegas et al, 2017; Martínez-García et al, 2019; Gaul et al, 2020). Therefore, pharmacological targeting of inflammasomes has been an area of intense research and investments by small biotech and big pharma companies. This has led to the development of small molecules targeting specific inflammasome sensor proteins, to avoid their activation (Coll et al, 2022). However, this might lead to (i) restrict their use to the diseases where the specifically targeted inflammasome sensor is involved, and (ii) reduce their therapeutic effects in already established inflammatory diseases, where post-inflammasome actors perpetuate the signaling by releasing the pro-inflammatory content of the cells dying by pyroptosis, which include the release of non-reversible prion-like ASC oligomers. Therefore, pyroptosis consequences would be hardly blocked by such inflammasome inhibitors, and novel blockers of GSDMD-induced pyroptosis are being developed (Coll et al, 2022). However, while blocking pyroptosis might appear as a novel approach to inhibit post-inflammasome-related signaling, inflammasome activation and accumulation of active caspase-1 may continue, potentially leading to alternative GSDMD-independent cell death and to the release of their pro-inflammatory content. In this context, targeting ASC is emerging as an alternative pathway to block multiple inflammasomes, and the small molecule MM01 has been recently identified as a blocker of ASC oligomerization triggered by different inflammasome sensors therefore, able to mitigate the disease in a pre-clinical model of gout (Soriano-Teruel et al, 2021). Similarly, the use of anti-ASC antibody to therapeutically neutralize ASC after its release from dying cells has reduced inflammasome signaling and its consequences in a rat model of traumatic brain injury (de Rivero Vaccari et al, 2009). In this issue of EMBO Molecular Medicine, Bertheloot et al. identify a novel ASC nanobody. Nanobodies, represent a promising novel class of biologic derived from single chain only camelid-antibodies. The antigen-binding domain derived from those camelid-antibodies can hence be used alone to produce a single-domain binding module, named VHH or nanobody, which represents the smallest known type of antibody. Here, the authors have generated and selected an anti-ASC nanobody based on its ability to bind and inhibit ASC oligomerization. Interestingly, the selected nanobody was also able to disaggregate already formed ASC oligomers inside the cells, provided that the nanobody gain access to the intracellular compartment, as well as ASC oligomers present in the extracellular milieu (Bertheloot et al, 2022). The authors demonstrated that the nanobody could indeed enter the cell through the GSDMD-pore induced at a late stage by inflammasome activation, resulting in the earlier termination of inflammasome activation and subsequent consequences (Fig 1). Contrary to classical antibodies, the small size of nanobodies, around 4 nm long and 2.5 nm wide, makes them compatible with entry through GSDMD-pores (estimated size of 10–15 nm). As this mechanism does not prevent early inflammasome activation, it is anticipated that such a strategy might not completely inhibit all the major infectious defence mechanisms, as opposed to therapeutic strategies that completely inhibit innate immunity, thus increasing the risk of infections. Perhaps more importantly, the selected nanobody was able to target extracellular ASC oligomers and prevent their extracellular signalling effects that are known to perpetuate and amplify inflammation in the vicinity of the cell dying from pyroptosis. Moreover, the nanobody was also demonstrated to disrupt the “prionoid” activities of ASC oligomers in the extracellular milieu that are supposed to promote the oligomerization of soluble ASC and to further aggravate inflammation (Fig 1). Finally, the authors demonstrated the therapeutic efficacy of their anti-ASC nanobody in a pre-clinical model of gout and in a model of antigen-induced arthritis (Bertheloot et al, 2022). This study broadens the toolbox to more precisely decipher the consequences of post-inflammasome signalling in the perpetuation of inflammation and tissue injury. This can be achieved in acute inflammatory models using direct anti-ASC nanobody injections, as well as in chronic disease, using for instance viral gene therapy vector to promote long-term expression in vivo. Such approaches could also be used to evaluate the possible relation between ASC-prionoid activity and amyloid aggregates in the brain using models of Alzheimer’s disease. Therefore, anti-ASC blocking nanobodies represent the next-generation of inflammasome-targeting biologics to tackle the detrimental consequences of inflammasome downstream signalling in already established inflammatory diseases. Figure 1. Mechanism of action of anti-ASC nanobody targeting ASC specks The activation of the inflammasome result in a large oligomer of ASC that is released during pyroptosis, leading to extracellular inflammatory functions in different diseases. ASC targeting nanobodies have the potential to disassemble ASC oligomers extracellularly and intracellularly, by penetrating the cell through gasdermin D pores. AD, Alzheimer's disease; CAPS, Cryopyrin-associated periodic syndrome; COPD, Chronic obstructive pulmonary disease; NAFLD, Nonalcoholic fatty liver disease; TBI, Traumatic brain injury. Download figure Download PowerPoint Disclosure statement and competing interests PP is the founder and consultant of Viva in vitro diagnostics SL, a company dedicated to use inflammasome for clinical diagnostics, and is also a consultant of Glenmark Pharmaceuticals and Monte Rosa Tex companies interested to develop inflammasome blockers. SA declare no conflict of interest. References Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe J, Ruiz-Ortiz E, Antón J et al (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15: 738–748CrossrefCASPubMedWeb of Science®Google Scholar Bertheloot D, Wanderley CW, Schneider AH, Schiffelers LD, Wuerth JD, Tödtmann JM, Maasewerd S, Hawwari I, Duthie F, Rohland C et al (2022) Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo. EMBO Mol Med 14: e15415Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Broz P, Pelegrín P, Shao F (2020) The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol 20: 143–157CrossrefCASPubMedWeb of Science®Google Scholar Coll RC, Schroder K, Pelegrín P (2022) NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci https://doi.org/10.1016/j.tips.2022.04.003CrossrefPubMedGoogle Scholar Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR, Al-Amoudi A et al (2014) The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol 15: 727–737CrossrefCASPubMedWeb of Science®Google Scholar Gaul S, Leszczynska A, Alegre F, Kaufmann B, Johnson CD, Adams LA, Wree A, Damm G, Seehofer D, Calvente CJ et al (2020) Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol 74: 30522–30525Google Scholar Martínez-García JJ, Martínez-Banaclocha H, Angosto-Bazarra D, de Torre-Minguela C, Baroja-Mazo A, Alarcón-Vila C, Martínez-Alarcón L, Amores-Iniesta J, Martín-Sánchez F, Ercole GA et al (2019) P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun 10: 2711CrossrefPubMedWeb of Science®Google Scholar de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD, Keane RW (2009) Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab 29: 1251–1261CrossrefCASPubMedWeb of Science®Google Scholar Soriano-Teruel PM, García‑Laínez G, Marco-Salvador M, Pardo J, Arias M, DeFord C, Merfort I, Vicent MJ, Pelegrín P, Sancho M et al (2021) Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases. Cell Death Dis 12: 1155CrossrefCASPubMedWeb of Science®Google Scholar Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP et al (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. Nature 552: 355–361CrossrefCASPubMedWeb of Science®Google Scholar Previous ArticleNext Article Read MoreAbout the coverClose modalView large imageVolume 14,Issue 6,08 June 2022This month's cover highlights the article Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo by Damien Bertheloot, Bernardo S. Franklin and colleagues. Inflammasome activation results in a caspase-1-driven lytic cell death named pyroptosis characterized by the leakage of intracellular content into the extracellular space. Inflammasomes themselves are released from dying cells in the form of ASC specks and were shown to accumulate in inflamed tissues. For long it remained unknown whether these protein complexes play a role in disease or were merely inert remnants of pyroptotic cell death. Alpaca-derived nanobodies raised against human and mouse ASC (VHHASC) can target and dissolve extracellular specks, neutralizing their inflammatory potential, and demonstrating for the first time their critical role in driving arthritis inflammation. (Cover concept by the authors; image design by SciStories) Volume 14Issue 68 June 2022In this issue FiguresReferencesRelatedDetailsLoading ..." @default.
• W4280494789 created "2022-05-22" @default.
• W4280494789 creator A5008112495 @default.
• W4280494789 creator A5024493210 @default.
• W4280494789 date "2022-05-16" @default.
• W4280494789 modified "2023-10-14" @default.
• W4280494789 title "ASC nanobodies to counteract the consequences of inflammasome activation" @default.
• W4280494789 cites W2012789061 @default.
• W4280494789 cites W2032370476 @default.
• W4280494789 cites W2143119237 @default.
• W4280494789 cites W2777928756 @default.
• W4280494789 cites W2952125019 @default.
• W4280494789 cites W2983652778 @default.
• W4280494789 cites W3047392456 @default.
• W4280494789 cites W4200398559 @default.
• W4280494789 cites W4224263277 @default.
• W4280494789 cites W4225416470 @default.
• W4280494789 cites W4280494789 @default.
• W4280494789 doi "https://doi.org/10.15252/emmm.202216087" @default.
• W4280494789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35574976" @default.
• W4280494789 hasPublicationYear "2022" @default.
• W4280494789 type Work @default.
• W4280494789 citedByCount "1" @default.
• W4280494789 countsByYear W42804947892022 @default.
• W4280494789 crossrefType "journal-article" @default.
• W4280494789 hasAuthorship W4280494789A5008112495 @default.
• W4280494789 hasAuthorship W4280494789A5024493210 @default.
• W4280494789 hasBestOaLocation W42804947893 @default.
• W4280494789 hasConcept C185592680 @default.
• W4280494789 hasConcept C203014093 @default.
• W4280494789 hasConcept C2776914184 @default.
• W4280494789 hasConcept C2777209026 @default.
• W4280494789 hasConcept C70721500 @default.
• W4280494789 hasConcept C86803240 @default.
• W4280494789 hasConcept C95444343 @default.
• W4280494789 hasConceptScore W4280494789C185592680 @default.
• W4280494789 hasConceptScore W4280494789C203014093 @default.
• W4280494789 hasConceptScore W4280494789C2776914184 @default.
• W4280494789 hasConceptScore W4280494789C2777209026 @default.
• W4280494789 hasConceptScore W4280494789C70721500 @default.
• W4280494789 hasConceptScore W4280494789C86803240 @default.
• W4280494789 hasConceptScore W4280494789C95444343 @default.
• W4280494789 hasFunder F4320310087 @default.
• W4280494789 hasFunder F4320322930 @default.
• W4280494789 hasFunder F4320332999 @default.
• W4280494789 hasFunder F4320334923 @default.
• W4280494789 hasIssue "6" @default.
• W4280494789 hasLocation W42804947891 @default.
• W4280494789 hasLocation W42804947892 @default.
• W4280494789 hasLocation W42804947893 @default.
• W4280494789 hasLocation W42804947894 @default.
• W4280494789 hasOpenAccess W4280494789 @default.
• W4280494789 hasPrimaryLocation W42804947891 @default.
• W4280494789 hasRelatedWork W1978688152 @default.
• W4280494789 hasRelatedWork W1983118497 @default.
• W4280494789 hasRelatedWork W1985538633 @default.
• W4280494789 hasRelatedWork W1997572777 @default.
• W4280494789 hasRelatedWork W2126693439 @default.
• W4280494789 hasRelatedWork W2477941193 @default.
• W4280494789 hasRelatedWork W2972371855 @default.
• W4280494789 hasRelatedWork W3025135158 @default.
• W4280494789 hasRelatedWork W4213451181 @default.
• W4280494789 hasRelatedWork W4313385396 @default.
• W4280494789 hasVolume "14" @default.
• W4280494789 isParatext "false" @default.
• W4280494789 isRetracted "false" @default.
• W4280494789 workType "article" @default.